Navigation Links
GW Pharmaceuticals plc Reports 2013 Q4 and Full Year Financial Results
Date:11/19/2013

e Company is poised to meet a number of significant clinical, regulatory and commercial milestones for GW investors. These include Phase 3 data from our U.S.-focused pivotal Sativex trials, further Sativex commercial launches and sales growth, progress of the new orphan epilepsy program in the U.S., and further advancement of several other cannabinoid pipeline candidates."

Conference Call and Webcast InformationGW Pharmaceuticals will host a conference call and webcast to discuss the 2013 financial results today at 8:00 a.m. ET / 1:00 p.m. GMT. To participate in the conference call, please dial 877-407-8133 (toll free from the U.S. and Canada), or 0-800-756-3429 (toll free from the UK) or 201-689-8040 (international). Investors may also access a live audio webcast of the call via the investor relations section of the Company's website at http://www.gwpharm.com. A replay of the call will also be available through the GW website shortly after the call and will remain available for 30 days. Replay Numbers: (toll free):1-877-660-6853, (international):1-201-612-7415. For both dial-in numbers please use conference ID # 13572702.

About GW Pharmaceuticals plcFounded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 22 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 The International Myeloma Foundation ... patients while working toward prevention and a cure – ... introducing a federal resolution (H. Res. 174) that supports ... "National Multiple Myeloma Awareness Month." Currently there ... and more than 110,000 new cases are diagnosed yearly, ...
(Date:3/27/2015)... , March 27, 2015  RXi ... privately-held MirImmune LLC, today announced that they ... to RXi,s novel and proprietary sd-rxRNA® technology ... immunotherapies. The collaboration has the potential to ... friendly cancer treatments that could be a ...
(Date:3/27/2015)... , March 27, 2015 ... 2015" therapeutic market research report of 52 pages ... online business intelligence library. The report ... on the therapeutic development for Visceral Pain, complete ... by drug target, mechanism of action (MoA), route ...
Breaking Medicine Technology:The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
... SAN DIEGO, Dec. 10, 2010 Arena Pharmaceuticals, Inc. ... of dosing in a Phase 1 clinical trial of ... that targets the prostacyclin receptor for the treatment of ... bioavailable prostacyclin receptor agonist could improve the standard of ...
... Dec. 9, 2010 United Seating & Mobility (USM) ... is excited to announce today that it has finalized a ... Business located in Little Rock, Arkansas. Alliance Homecare ... services including oxygen, DME and sleep therapy in the Little ...
Cached Medicine Technology:Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension 4United Seating & Mobility Reaches Agreement With Alliance Homecare Equipment to Acquire its Complex Mobility Business 2
(Date:3/27/2015)... Mirada, CA (PRWEB) March 27, 2015 ... physician, Stanley G. Katz, M.D., is now treating knee ... California, including Anaheim , Long Beach, and La ... treatment of acute knee and hip joint disorders as ... Stanley Katz is passionate in returning his patients back ...
(Date:3/27/2015)... San Jose, CA (PRWEB) March 27, 2015 ... last week’s 2015 GPU technology conference (GTC) , the ... to fight cancer and push the human lifespan well beyond ... Baltimore MD informatics company , is one of 12 ... , While other startups in the GTC Emerging ...
(Date:3/27/2015)... 2015 On March 19, 2015, ... Detroit Lions wide receiver Herman Moore, hosted “Fighting ... on substance abuse, treatment options and the recent ... were pastors, ministers and bishops from local churches ... guests. , “Our ‘Fighting Addiction Together’ luncheon was ...
(Date:3/27/2015)... FL and London, UK (PRWEB) March 27, 2015 ... announced today that it has appointed Sean Fitzgerald, a ... role of Chief Operating Officer and Interim Chief Financial ... President of leading education technology innovator, EverFi, backed by ... Schmidt, and Twitter founder Evan Williams. Prior to EverFi, ...
(Date:3/27/2015)... WA (PRWEB) March 27, 2015 When ... can be hard to know where to begin. The ... experienced Seattle trucking accident attorney, offers accident victims a ... and legal assistance to ensure their personal injury claim ... begins by describing the first actions that should be ...
Breaking Medicine News(10 mins):Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:LiveToBeSober.org Hosts Conference on Substance Abuse Treatment and Recovery at Ford Field 2Health News:GenSight Appoints Former Technology Executive as Chief Operating Officer 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2
... , TUESDAY, Nov. 16 (HealthDay News) -- Men who ... disease, new research suggests. The notion is based on ... a thickening of the men,s neck,s carotid artery wall. Such ... for heart disease. What,s more, the link between sleep ...
... TUESDAY, Nov. 16 (HealthDay News) -- A rare, but ... hyperemesis gravidarum, may be hereditary, researchers say. Each ... are hospitalized due to hyperemesis gravidarum (HG), marked by ... cause weight loss, dehydration and psychological trauma. The condition, ...
... , TUESDAY, Nov. 16 (HealthDay News) -- Bouts ... behavior over time, including their propensity for more heavy drinking, ... 500 boys in Pittsburgh who were assessed each year from ... four to five years later. When they were teens, ...
... Three-year-old Denver resident Brianna,s favorite color was yellow and her ... At 18 months she strapped on her first pair of ... loved playing with her brother and noticed everything. ... from a cardiac arrhythmia known as Long QT Syndrome. Brianna,s ...
... N.C. The National Institutes of Health (NIH), National ... Duke University Medical Center up to $52.8 million over ... and oversight of external quality assurance programs that monitor ... around the world. The project, External Quality ...
... Nov. 16 (HealthDay News) -- Hospital care-related problems contribute ... month, according to a new federal government study. ... including infections, bed sores and excessive bleeding from blood-thinning ... patients discharged from hospitals in October 2008, USA ...
Cached Medicine News:Health News:Shorter Sleep in Men Ups Risk of Heart Disease: Study 2Health News:Rare, Severe Form of Morning Sickness Appears to Be Genetic 2Health News:For Teen Boys, Heavy Drinking & Impulsivity May Be Vicious Circle 2Health News:University of Colorado in pilot project to map defibrillators 2Health News:Duke to lead oversight of HIV laboratories worldwide 2Health News:Duke to lead oversight of HIV laboratories worldwide 3Health News:Hospital Care Deadly for Some, U.S. Study Finds 2
... achieves optimum lung penetration for maximum therapeutic ... 1.04-1.10 µ at 6-8 LPM. Latex-free components. ... ,As the world leader in airway management ... of proven technology by offering top brands ...
... nebulizer the gold standard for continuous medication delivery. ... together in one convenient kit. You asked, and ... HOPE Kit which contains a HOPE nebulizer, 6 ... all in one set up. This kit has ...
... offer a spill-proof design and effective output, ... angle. All medical nebulizers are free-standing for ... configurations are available., ,All Portex® medication ... medication nebulizers feature consistently fine misting and ...
... everything the health care professional needs to ... efficiently: 7 nebulizers, T-piece and mouthpiece, exhalation ... ,Shipped 5 kits per case., ... ,Intended Use: AsthmaKit is a procedural kit ...
Medicine Products: